de.mpg.escidoc.pubman.appbase.FacesBean
Deutsch
 
Hilfe Wegweiser Impressum Kontakt Einloggen
  DetailsucheBrowse

Datensatz

DATENSATZ AKTIONENEXPORT

Freigegeben

Zeitschriftenartikel

The new Sulindac derivative IND 12 reverses Ras-induced cell transformation

MPG-Autoren

Karaguni,  Ioanna-Maria
Max Planck Institute of Molecular Physiology, Max Planck Society;

Herter,  Peter
Max Planck Institute of Molecular Physiology, Max Planck Society;

http://pubman.mpdl.mpg.de/cone/persons/resource/persons98686

Chtarbova,  Slava
Abt. IV: Chemische Biologie, Max Planck Institute of Molecular Physiology, Max Planck Society;

Kasprzynski,  Alice
Max Planck Institute of Molecular Physiology, Max Planck Society;

Herbrand,  Ulrike
Max Planck Institute of Molecular Physiology, Max Planck Society;

http://pubman.mpdl.mpg.de/cone/persons/resource/persons98673

Ahmadian,  Mohammad Reza
Sonstige Wissenschaftliche Organisationseinheiten, Max Planck Institute of Molecular Physiology, Max Planck Society;

http://pubman.mpdl.mpg.de/cone/persons/resource/persons98712

Müller,  Oliver
Sonstige Wissenschaftliche Organisationseinheiten, Max Planck Institute of Molecular Physiology, Max Planck Society;

Externe Ressourcen
Es sind keine Externen Ressourcen verfügbar
Volltexte (frei zugänglich)
Es sind keine frei zugänglichen Volltexte verfügbar
Ergänzendes Material (frei zugänglich)
Es sind keine frei zugänglichen Ergänzenden Materialien verfügbar
Zitation

Karaguni, I.-M., Herter, P., Debruyne, P., Chtarbova, S., Kasprzynski, A., Herbrand, U., et al. (2002). The new Sulindac derivative IND 12 reverses Ras-induced cell transformation. Cancer Research, 62(6): 1, pp. 1718-1723. Retrieved from http://cancerres.aacrjournals.org/cgi/content/abstract/62/6/1718.


Zitierlink: http://hdl.handle.net/11858/00-001M-0000-0014-0EC6-E
Zusammenfassung
The nonsteroidal anti-inflammatory drug Sulindac has chemopreventive and antitumorigenic properties. Its metabolites induce apoptosis and inhibit signaling pathways critical for malignant transformation, including the Ras pathway. Here we show that the new Sulindac derivative IND 12 reverses the phenotype of Ras-transformed MDCK-f3 cells and restores an untransformed epithelioid morphology characterized by growth in monolayers with regular cell-cell adhesions. Moreover, IND 12 treatment induces the expression at membranes of the cell adhesion protein E-cadherin and increases the level of the E- cadherin-bound beta-catenin. As a consequence, IND 12-treated MDCK-f3 cells lose their invasion capacity and regain the ability to aggregate. In the presence of IND 12, MDCK-f3 cells show regenerated expression and activity ratios of the small GTPases Rac and Rho normally found in untransformed MDCK cells. Strikingly, IND 12 treatment decreases the levels of phosphorylated mitogen-activated protein kinases, which are downstream substrates of the Ras-regulated Raf/mitogen- activated protein kinase pathway, and the level of Ras-induced activation of gene expression. Our findings identify a novel drug with high potential in cancer therapy by targeting Ras- induced cell transformation.